Progression of dopaminergic dysfunction in a LRRK2 kindred: A multitracer PET study

R. Nandhagopal, E. Mak, M. Schulzer, J. McKenzie, S. McCormick, V. Sossi, T. J. Ruth, A. Strongosky, M. J. Farrer, Z. K. Wszolek, A. J. Stoessl

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Objective: Little is known about the progression of dopaminergic dysfunction in LRRK2associated Parkinson disease (PD). We sought to characterize the neurochemical progression with multitracer PET in asymptomatic members of parkinsonian kindred (family D, Western Nebraska) carrying LRRK2 (R1441C) mutation. Method: Thirteen family D subjects underwent PET scans of presynaptic dopaminergic integrity and five subjects were rescanned 2 to 3 years later. Results: In subjects 8, 9 (mutation carriers), and 13 (genealogically at risk subject), there was a decline in PET markers over the course of the study that was significantly greater than the expected rate of decline in healthy controls. Reduced dopamine transporter binding was the earliest indication of subclinical dopaminergic dysfunction and progression to clinical disease was generally associated with the emergence of abnormal fluorodopa uptake. Conclusion: PET study of presymptomatic members of our LRRK2 kindred revealed dopaminergic dysfunction that progressed over time. This represents an ideal group to study the natural history of early disease and the potential effects of neuroprotective interventions.

Original languageEnglish
Pages (from-to)1790-1795
Number of pages6
JournalNeurology
Volume71
Issue number22
DOIs
Publication statusPublished - Nov 25 2008

Fingerprint

Dopamine Plasma Membrane Transport Proteins
Mutation
Positron-Emission Tomography
Parkinson Disease
fluorodopa F 18

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Nandhagopal, R., Mak, E., Schulzer, M., McKenzie, J., McCormick, S., Sossi, V., ... Stoessl, A. J. (2008). Progression of dopaminergic dysfunction in a LRRK2 kindred: A multitracer PET study. Neurology, 71(22), 1790-1795. https://doi.org/10.1212/01.wnl.0000335973.66333.58

Progression of dopaminergic dysfunction in a LRRK2 kindred : A multitracer PET study. / Nandhagopal, R.; Mak, E.; Schulzer, M.; McKenzie, J.; McCormick, S.; Sossi, V.; Ruth, T. J.; Strongosky, A.; Farrer, M. J.; Wszolek, Z. K.; Stoessl, A. J.

In: Neurology, Vol. 71, No. 22, 25.11.2008, p. 1790-1795.

Research output: Contribution to journalArticle

Nandhagopal, R, Mak, E, Schulzer, M, McKenzie, J, McCormick, S, Sossi, V, Ruth, TJ, Strongosky, A, Farrer, MJ, Wszolek, ZK & Stoessl, AJ 2008, 'Progression of dopaminergic dysfunction in a LRRK2 kindred: A multitracer PET study', Neurology, vol. 71, no. 22, pp. 1790-1795. https://doi.org/10.1212/01.wnl.0000335973.66333.58
Nandhagopal, R. ; Mak, E. ; Schulzer, M. ; McKenzie, J. ; McCormick, S. ; Sossi, V. ; Ruth, T. J. ; Strongosky, A. ; Farrer, M. J. ; Wszolek, Z. K. ; Stoessl, A. J. / Progression of dopaminergic dysfunction in a LRRK2 kindred : A multitracer PET study. In: Neurology. 2008 ; Vol. 71, No. 22. pp. 1790-1795.
@article{23d3135c41ba44cd8ade482a13f3dba5,
title = "Progression of dopaminergic dysfunction in a LRRK2 kindred: A multitracer PET study",
abstract = "Objective: Little is known about the progression of dopaminergic dysfunction in LRRK2associated Parkinson disease (PD). We sought to characterize the neurochemical progression with multitracer PET in asymptomatic members of parkinsonian kindred (family D, Western Nebraska) carrying LRRK2 (R1441C) mutation. Method: Thirteen family D subjects underwent PET scans of presynaptic dopaminergic integrity and five subjects were rescanned 2 to 3 years later. Results: In subjects 8, 9 (mutation carriers), and 13 (genealogically at risk subject), there was a decline in PET markers over the course of the study that was significantly greater than the expected rate of decline in healthy controls. Reduced dopamine transporter binding was the earliest indication of subclinical dopaminergic dysfunction and progression to clinical disease was generally associated with the emergence of abnormal fluorodopa uptake. Conclusion: PET study of presymptomatic members of our LRRK2 kindred revealed dopaminergic dysfunction that progressed over time. This represents an ideal group to study the natural history of early disease and the potential effects of neuroprotective interventions.",
author = "R. Nandhagopal and E. Mak and M. Schulzer and J. McKenzie and S. McCormick and V. Sossi and Ruth, {T. J.} and A. Strongosky and Farrer, {M. J.} and Wszolek, {Z. K.} and Stoessl, {A. J.}",
year = "2008",
month = "11",
day = "25",
doi = "10.1212/01.wnl.0000335973.66333.58",
language = "English",
volume = "71",
pages = "1790--1795",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "22",

}

TY - JOUR

T1 - Progression of dopaminergic dysfunction in a LRRK2 kindred

T2 - A multitracer PET study

AU - Nandhagopal, R.

AU - Mak, E.

AU - Schulzer, M.

AU - McKenzie, J.

AU - McCormick, S.

AU - Sossi, V.

AU - Ruth, T. J.

AU - Strongosky, A.

AU - Farrer, M. J.

AU - Wszolek, Z. K.

AU - Stoessl, A. J.

PY - 2008/11/25

Y1 - 2008/11/25

N2 - Objective: Little is known about the progression of dopaminergic dysfunction in LRRK2associated Parkinson disease (PD). We sought to characterize the neurochemical progression with multitracer PET in asymptomatic members of parkinsonian kindred (family D, Western Nebraska) carrying LRRK2 (R1441C) mutation. Method: Thirteen family D subjects underwent PET scans of presynaptic dopaminergic integrity and five subjects were rescanned 2 to 3 years later. Results: In subjects 8, 9 (mutation carriers), and 13 (genealogically at risk subject), there was a decline in PET markers over the course of the study that was significantly greater than the expected rate of decline in healthy controls. Reduced dopamine transporter binding was the earliest indication of subclinical dopaminergic dysfunction and progression to clinical disease was generally associated with the emergence of abnormal fluorodopa uptake. Conclusion: PET study of presymptomatic members of our LRRK2 kindred revealed dopaminergic dysfunction that progressed over time. This represents an ideal group to study the natural history of early disease and the potential effects of neuroprotective interventions.

AB - Objective: Little is known about the progression of dopaminergic dysfunction in LRRK2associated Parkinson disease (PD). We sought to characterize the neurochemical progression with multitracer PET in asymptomatic members of parkinsonian kindred (family D, Western Nebraska) carrying LRRK2 (R1441C) mutation. Method: Thirteen family D subjects underwent PET scans of presynaptic dopaminergic integrity and five subjects were rescanned 2 to 3 years later. Results: In subjects 8, 9 (mutation carriers), and 13 (genealogically at risk subject), there was a decline in PET markers over the course of the study that was significantly greater than the expected rate of decline in healthy controls. Reduced dopamine transporter binding was the earliest indication of subclinical dopaminergic dysfunction and progression to clinical disease was generally associated with the emergence of abnormal fluorodopa uptake. Conclusion: PET study of presymptomatic members of our LRRK2 kindred revealed dopaminergic dysfunction that progressed over time. This represents an ideal group to study the natural history of early disease and the potential effects of neuroprotective interventions.

UR - http://www.scopus.com/inward/record.url?scp=58149242840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149242840&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000335973.66333.58

DO - 10.1212/01.wnl.0000335973.66333.58

M3 - Article

C2 - 19029519

AN - SCOPUS:58149242840

VL - 71

SP - 1790

EP - 1795

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 22

ER -